Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes

Atherosclerosis

Volumn 168, Issue 1, 2003, Pages 169-179

  Playford, David A ^a   Watts, Gerald F ^a   Croft, Kevin D ^a   Burke, Valerie ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Coenzyme Q10; Diabetes; Fenofibrate; Vasculopathy

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; BRADYKININ; CHOLESTEROL; ENDOTHELIUM DERIVED RELAXING FACTOR; FENOFIBRATE; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; ISOPROSTANE; METFORMIN; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UBIDECARENONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM; FEMALE; FIBRINOGEN BLOOD LEVEL; FOREARM; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ACETYLCHOLINE; ANTILIPEMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; AREA UNDER CURVE; BLOOD CIRCULATION; BLOOD PRESSURE; BRADYKININ; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; F2-ISOPROSTANES; FEMALE; FOREARM; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; PROCETOFEN; REGIONAL BLOOD FLOW; STATISTICS; SYSTOLE; TREATMENT OUTCOME; TRIGLYCERIDES; UBIQUINONE; VASODILATOR AGENTS;

EID: 0038065548     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00417-3     Document Type: Article

References (48)

1. Cohen R.A. Dysfunction of vascular endothelium in diabetes mellitus. Circulation. 87:(Suppl V):1993;V67-V76.
2. Watts G.F., Playford D.A. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis. 141:1998;7-30.
3. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
4. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary heart disease. Circulation. 27:(104):2001;2673-2678.
5. Watts G.F., O'Brien S.F., Silvester W., Millar J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin. Sci. 91:1996;567-573.
6. O'Brien S.F., Watts G.F., Playford D.A., Burke V., O'Neal D.A., Best J.D. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet. Med. 14:1997;974-978.
7. Anderson R.A., Evans M.L., Ellis G.R., et al. The relationship between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis. 154:2002;475-483.
8. Watts G.F., Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr. Opin. Lipidol. 10:1999;561-574.
9. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:1999;410-418.
10. Elkeles R.S., Diamond J.R., Poulter C., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 21:1998;641-648.
11. Steiner G, Hamston A, Hosking J et al. for the Diabetes Atherosclerosis Intervention Study Investigators: effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357: 905-910.
12. Malik J., Melenovsky V., Wichterle D., et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastin trial - FAT). Cardiovas. Res. 52:2001;290-298.
13. Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr. Opin. Lipidol. 10:1999;589-597.
14. Skyrme-Jones R.A., O'Brien R.C., Berry K.L., Meredith I.T. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J. Am. Coll. Cardiol. 36:2000;94-102.
15. Gazis A., White D.J., Page S.R., Cockcroft J.R. Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet. Med. 16:1999;304-311.
16. Chowienczyk P.J., Brett S.E., Gopaul N.K., et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with Type II diabetes. Diabetologia. 43:2000;974-977.
17. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28.
18. Perticone F., Ceravalo R., Candigliota M., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 50:2001;159-165.
19. Heitzer T., Finckh B., Albers S., Krohn K., Kohlschutter A., Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation diabetic patients: relation to parameters of oxidative stress. Free Radical Biol. Med. 31:2001;53-61.
20. Beyer R.E. The participation of coenzyme Q in free radical production and anti-oxidation. Free Radical Biol. Med. 8:1990;465-545.
21. McCarthy M.F. Coenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation? Med. Hypotheses. 53:1999;300-304.
22. Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does α-topopherol. Proc. Natl. Acad. Sci. USA. 88:1991;1646-1650.
23. Thomas S.R., Neuzil J., Stocker R. Co-supplementation with coenzyme Q prevents the proxidant effect of α-tocopherol and increase in the resistance of LDL to transition metal-dependent oxidation initiation. Atherioscler. Thromb. Vasc. Biol. 16:1996;687-696.
24. 10 alpha-tocopherol, and free cholesterol levels in sera from diabetic patients. Folkers K., Littarru G., Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. 1991;151-158 Elsevier Science, Amsterdam.
25. McCarthy M.F. Can correction of sub-optimal coenzyme Q status improve β-cell function in type II diabetes? Med. Hypotheses. 52:1999;368-397.
26. Thomas S.R., Witting P.K., Stocker R. A role for reduced coenzyme Q in atherosclerosis? Biofactors. 9:1999;207-224.
27. Lang J.K., Gohil K., Packer L. Simultaneous determination of tocopherols, ubiquinols and ubiquinones in blood plasma, tissue homogenates and subcellular fractions. Anal. Biochem. 157:1986;106-116.
28. 2-isoprostanes using Gas Chromatography Mass Spectrometry. Anal. Biochem. 268:1999;117-125.
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419.
30. Simons L.A., von Konigsmark M., Simons J., Stocker R., Celermajer D.S. Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis. 143:1999;193-199.
31. Evans M., Anderson R.A., Graham J., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 101:2000;1773-1779.
32. Avogaro A., Miola M., Favaro A., et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilation in type 2 diabetic patients. Eur. Clin. Invest. 31:2001;603-609.
33. Cohen R.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization. Circulation. 92:1995;3337-3349.
34. Aydin A., Orhan H., Sayal A., Ozata M., Sahin G., Isimer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin. Biochem. 34:2001;65-70.
35. Flavahan N.A. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 85:1992;1927-1938.
36. De Vriese A.S., Verbeuren T.J., Van der Voorde J., Lameire N.H., Vanhoutte P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 13:2000;963-974.
37. 10 improves endothelial dysfunction of the brachial artery in type 2 diabetes mellitus. Diabetologia. 45:2002;420-426.
38. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 99:1999;224-229.
39. Williams S.B., Goldfine A.B., Timimi F.K., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 97:1998;1695-1701.
40. Poderoso J.J., Carreras M.C., Schopfer F., et al. The reaction of nitric oxide with ubiquinol: kinetic properties and biological significance. Free Radical Biol. Med. 26:1999;925-935.
41. 10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur. J. Clin. Nutr. 56:2002;1-6.
42. Chakravarthy U., Hayes R.G., Stitt A.W., McAuley E., Archer D.B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes. 47:1998;945-952.
43. Meagher E.A., FitzGerald G.A. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radical Biol. Med. 28:2000;1745-1750.
44. Kugiyama K., Doi H., Motoyama T., et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 97:1998;2519-2526.
45. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10:1999;245-257.
46. Bissonnette R., Treacy E., Rozen R., Boucher B., Cohn J.S., Genest J. Jr. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 155:2001;455-462.
47. Nitenberg A., Valensi P., Sachs R., Dali M., Aptecar E., Attali J.R. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 42:1993;1017-1025.
48. Suwaidi J.A., Hamasake S., Higano S.T., Nishimura R.A., Holmes D.R., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954.